Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

The step reflects Takeda's strategic commitment to Asia and to China in particular. Takeda is now enhancing its business in China through TCH's wholly owned subsidiaries, Takeda Pharmaceutical (China) in Taizhou, responsible for manufacturing, and Tianjin Takeda Pharmaceuticals in Tianjin, responsible for marketing and sales. With them, TSDC will help drive Takeda's growth agenda in China and in the broader Asian region.

Within Asia outside Japan, including China, drug development is overseen by Takeda Global Research & Development Center (Asia) in Singapore and Millennium Pharmaceuticals in Cambridge, Mass., wholly owned subsidiaries of Takeda, through outsourcing to CROs. TSDC will work to extend the company's clinical development activities within Asia, with a focus on China for general medicine and across Asia for Oncology. The team will be composed of personnel from both the Pharmaceutical Development Division and Millennium.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs